PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that interim analysis of its Phase IIb trial has provided further supportive evidence of the monepantel blood plasma levels required to suppress B cell lymphoma growth in pet owners’ dogs.
PharmAust is now in a good position to further optimize treatment levels of MPL to facilitate a Phase III study. Monepantel in this stage of the study indicated no material adverse events.
PharmAust’s Chief Scientific Officer Dr. Richard Mollard stated, “As per the previous high-dose trial using monepantel tablets, a range of drug blood plasma levels was again observed in this lower dose trial, but this time all within a narrower spread. Examination of the blood plasma data in the context of the previous trial, while referencing side effects and efficacy, has reinforced our understanding of a target therapeutic window for monepantel’s use in dogs with B cell lymphoma. The Phase IIb trial will continue to increase recruitment numbers to gain sufficient information for a future Phase III registration trial.”
PharmAust’s Chairman, Dr Roger Aston stated, “This represents a material advance in optimizing the treatment regimen for canine patients with B-Cell lymphoma and may have applicability to other anticancer treatments in companion animals and in humans. Cancer therapy is all about optimizing efficacy and minimizing adverse events and this is particularly important with aggressive late-stage cancers such a Stage 4/5 B-Cell lymphoma. Following a Phase III trial PharmAust will also examine how monepantel can be integrated into the current standard of care.”